Alpha adrenoceptor antagonists in the year 2000: is there anything new?
Selective alpha1-adrenergic blockade is now a well accepted and widely used therapeutic treatment for patients presenting with symptomatic bladder outlet obstruction thought to be associated with benign prostatic hyperplasia. This review summarizes the recent developments in this field relating to the subject of receptor subtype selectivity and the potential relevance of this to clinical usefulness of existing drug therapy. Whilst a number of unanswered questions remain as to the exact mechanisms of both drug action and side-effect profile, nevertheless it is clear that existing clinically available alpha1-antagonists provide a safe, effective and generally well tolerated therapy for patients with lower urinary tract symptoms thought to be associated with benign prostatic obstruction. The implications of the ALLHAT study are discussed.
Chapple
C R
CR
Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK. c.r.chapple@sheffield.ac.uk
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008297:Male; D011467:Prostate / Q000187:drug effects / Q000502:physiology; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D001743:Urinary Bladder / Q000502:physiology; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000209:etiology
D000317:Adrenergic alpha-Antagonists; D011942:Receptors, Adrenergic, alpha